Source: CMAJ
Area: News
Following reports of inflammatory ocular adverse events, mainly uveitis and scleritis, among patients on oral bisphosphonates, this retrospective cohort study examined the risk of these adverse events in residents of British Columbia who had visited an ophthalmologist from 2000 to 2007.
The cohort comprised 934,147 people, including 10,827 first-time users of bisphosphonates and 923,320 non-users, who were followed to the first inflammatory ocular adverse event, death, termination of insurance or the end of the study period. An inflammatory ocular adverse event was defined as scleritis or uveitis.
The following findings were reported:
. The incidence rate among first-time users was 29/10,000 person-years for uveitis and 63/10,000 person-years for scleritis.
. The incidence among people who did not use oral bisphosphonates was 20/10,000 person-years for uveitis and 36/10,000 for scleritis (number needed to harm: 1100 and ...
Uncategorized